Chugai Pharmaceutical (OTCMKTS:CHGCY) Lowered to Hold Rating by UBS Group

Chugai Pharmaceutical (OTCMKTS:CHGCY) was downgraded by analysts at UBS Group from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Thursday,Zacks.com reports.

Several other analysts have also recently weighed in on the company. Zacks Research raised Chugai Pharmaceutical to a “hold” rating in a report on Friday, May 29th. The Goldman Sachs Group raised Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a report on Monday, June 15th. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy”.

Chugai Pharmaceutical Stock Up 2.9%

Shares of OTCMKTS:CHGCY opened at $21.66 on Thursday. The firm has a market capitalization of $71.29 billion, a PE ratio of 23.54 and a beta of 0.60. The company has a 50-day moving average price of $22.70 and a two-hundred day moving average price of $26.02. Chugai Pharmaceutical has a twelve month low of $20.00 and a twelve month high of $34.84.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last posted its quarterly earnings results on Friday, July 24th. The company reported $0.22 earnings per share (EPS) for the quarter. The company had revenue of $2.14 billion for the quarter, compared to analyst estimates of $2.38 billion. Chugai Pharmaceutical had a net margin of 35.09% and a return on equity of 23.71%. Analysts anticipate that Chugai Pharmaceutical will post 0.96 earnings per share for the current fiscal year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.